Billionaire Peter Thiel Acquires 7.5% Stake in Crypto Firm 180 Life Sciences Corp, Shares Jump 182%

Peter Thiel's investment in 180 Life Sciences Corp has led to a 182% jump in shares, with the company's stock price reaching $9.490. Thiel acquired a 7.5% stake through his venture capital fund, Founders Fund Growth Management. The company has shifted its focus from biotech to digital asset treasury, holding 82,186 ether worth approximately $349 million. Thiel is also a 9.1% shareholder in BitMine, which increased its at-the-market equity program to $24.5 billion to finance additional Ethereum acquisitions.

Peter Thiel's investment in 180 Life Sciences Corp has led to a dramatic 182% jump in shares, with the company's stock price reaching $9.490. Thiel acquired a 7.5% stake through his venture capital fund, Founders Fund Growth Management [1]. The company has shifted its focus from biotech to digital asset treasury, holding 82,186 ether worth approximately $349 million. Thiel is also a 9.1% shareholder in BitMine, which increased its at-the-market equity program to $24.5 billion to finance additional Ethereum acquisitions [2].

180 Life Sciences Corp, previously known as 180 Life Sciences, rebranded as ETHZilla Corporation and raised $156 million through senior secured convertible notes and $425 million via a private placement to fund Ethereum (ETH) purchases, yield-bearing assets, iGaming operations, and monetization of its biotech IP [1]. The company aims to become a leading corporate ETH holder, with 82,186 ETH already acquired.

Thiel's investment marks his second significant bet on Ethereum-focused corporate treasuries, following a 9% stake in BitMine Immersion (BMNR), which holds approximately $5 billion in ETH [1]. The biotech-turned-crypto firm's aggressive capital raises, totaling $581 million, position it to amass substantial ETH reserves. This pivot reflects a broader shift among public companies exploring cryptocurrencies as a hedge against inflation and a source of innovative financial strategies, though it carries risks tied to Ethereum's price volatility and regulatory uncertainties [1].

As 180 Life Sciences navigates this transformation, Thiel's backing and the company's substantial capital influx signal a high-stakes bet on Ethereum's role in reshaping corporate finance. The company's strategic shift centers on leveraging Ethereum (ETH) as a core treasury asset, with plans to optimize returns through decentralized finance (DeFi) strategies [1]. The involvement of Thiel, a prominent figure in tech and crypto investment, underscores the market's confidence in ETHZilla's vision to become a benchmark for on-chain treasury management.

References:
[1] https://wallstreetpit.com/128399-peter-thiels-7-5-stake-ignites-230-rally-in-180-life-sciences/
[2] https://www.stocktitan.net/sec-filings/ATNFW/schedule-13g-180-life-sciences-corp-warrant-sec-filing-f403edfa5fa5.html